Document is current
Any future updates will be listed below
-
Authors
Zhang, Hong
Li, Qianqian
Chen, Hong
Guo, Lingfeng
Li, Jing
Xie, Can
Yan, Jiangyu
Ding, Yanhua
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05943886 at ClinicalTrials.govDocuments that mention this clinical trial
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
https://doi.org/10.1136/gutjnl-2025-337431
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
https://doi.org/10.1007/s40259-025-00715-3
-
Funding
Funding for this research was provided by:
Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd
- License Information
-
More Information
Article History
Accepted: 17 March 2025
First Online: 3 April 2025
Declarations
:
: This clinical study was sponsored by Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd..
: Lingfeng Guo, Jing Li, Can Xie, and Jiangyu Yan are employees of Dongguan HEC Biopharmaceutical R&D Co., Ltd. and Sunshine Lake Pharma Co., Ltd. Hong Zhang, Qianqian Li, Hong Chen, and Yanhua Ding have no conflicts of interest that are directly relevant to the content of this article.
: The study protocol was approved by the Ethics Committee of The First Hospital of Jilin University (Changchun, Jilin, China, reference number: 21Y098-002) on 29 April, 2021. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guideline.
: All patients in this study provided written informed consent to participate.
: Not applicable.
: The datasets supporting the conclusions of this article are available from the corresponding author upon reasonable request.
: Not applicable.
: HZ, QL, HC, JY, and YD contributed to the conception and design of the work, as well as analyses of the data; HZ, QL, and HC managed the clinical trial and performed data acquisition and interpretation; LG, JL, CX, and JY carried out the preclinical studies; HZ wrote the manuscript; HZ, JY, and YD revised the manuscript for intellectual content and collectively approved the final version to be published; and all authors agreed to be accountable for all aspects of the work.
